Please login to the form below

Not currently logged in
Email:
Password:

Jazz Pharmaceuticals

This page shows the latest Jazz Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Jazz Pharma’s SCLC drug fails to meet primary endpoint in combo trial

Jazz Pharma’s SCLC drug fails to meet primary endpoint in combo trial

Drug combination failed to improve overall survival rate. Jazz Pharmaceuticals and PharmaMar have revealed that their small cell lung cancer (SCLC) therapy lurbinectedin has failed to meet the primary endpoint in ... Robert Iannone, executive vice

Latest news

More from news
Approximately 4 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • Deal Watch July 2016 Deal Watch July 2016

    Jazz Pharmaceuticals paid $15m in upfront and option payments to Pfenex for the rights to a portfolio of early stage products in haematology/oncology. ... Sprint BioScience/ Petre Pharma. PIP4K2a inhibitor programme. Licence. 240. Pfenex/ Jazz

  • Pharma deals in March 2015 Pharma deals in March 2015

    The other deal of interest is the re-emergence of EUSA Pharma with products acquired from Jazz Pharmaceuticals. ... investor, Essex Woodlands, has bought back products worth $27m and the EUSA Pharma name from Jazz for an undisclosed amount.

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    3, 080. Cosmo Technologies/ Salix Pharmaceuticals. Merger (tax inversion)    . Portfolio of treatments for gastrointestinal disease and disorders. ... 360. Sigma-Tau/ Jazz Pharmaceuticals. Regaining rights. Defibrotide for severe hepatic

  • Deal Watch table for January 2014 Deal Watch table for January 2014

    490. Aerial BioPharma/ Jazz Pharmaceuticals. Product rights. Jazz gain access to ADX N05 for treatment of narcolepsy, SK Biopharmaceuticals retain some Asian rights, upfront of $125m, Aerial and SK receive milestones ... 100. Cancer Prevention

  • Pharma deals during September 2012 Pharma deals during September 2012

    Dual-affinity re-targeting (DART) platform technology for cancer targets. 1, 100. Selexys Pharmaceuticals  / Novartis Pharmaceuticals. ... Jazz Pharmaceuticals / Meda. Division acquisition. Women's health division. 95. NextMed (Apricus Bio)   / Takeda

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Dan Russell joins Seven Stones as managing director Dan Russell joins Seven Stones as managing director

    At Seven Stones, Russell will work alongside the agency’s chief creative officer and founder Alex Perryman to build on the company’s reputation with clients, which includes Bayer, GE, Jazz ... Pharmaceuticals, MSD and more.

  • EUSA Pharma appoints Lee Morley as its new chief executive EUSA Pharma appoints Lee Morley as its new chief executive

    Morton originally founded EUSA in 2005, leading it until its 2012 acquisition by Jazz Pharmaceuticals for $700m and then taking the reins again last month when EUSA was once again launched ... business. Prior to his time with Jazz, and before that the pre

  • EUSA Pharma founder to chair Glide Pharma EUSA Pharma founder to chair Glide Pharma

    EUSA was sold to Jazz Pharmaceuticals in 2012 for $700m. His other entrepreneurial experience in the industry includes founding Zeneus Pharma, which was acquired by Cephalon for $360m.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Iguazu Iguazu

    MSD. Sanofi Genzyme. Roche. Merck. Daiichi-Sankyo. Jazz Pharmaceuticals. Gedeon Richter. EUSA Pharma. ... Philip Higgins. Jazz Pharmaceuticals. 0118 3913 664. Address:. Flagstaff House. 14 High Street, Twyford.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Graphite Digital

We’re a digital CX agency collaborating with healthcare and pharmaceutical organisations to help them connect more deeply with their audiences...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...